drugset / Trial / NCT01511250

Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years

NCT01511250 ↗

Phase 2 Completed 360 enrolled Takeda
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to assess the safety of Takeda's tetravalent dengue vaccine (TDV) (previously DENVax) administered subcutaneously in healthy adults and children. In addition the antibody response to the four dengue virus serotypes will be evaluated.

Timeline

Start
2011-11-16
Primary completion
2016-04-01
Completion
2016-04-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-003 Vaccine 0.5 ml Subcutaneous

Indications

No indication recorded.